Turn Biotechnologies Expands Epigenetic Therapies with ARMMs Technology Acquisition

In a significant leap forward for epigenetic medicine, Turn Biotechnologies, a pioneering company in epigenetic reprogramming, has announced its acquisition of the ARMMs technology, which stands for ARRDC1 Mediated Microvesicles. This groundbreaking technology aims to enhance the precision and reach of Turn's therapies for various tissues and organs, ultimately allowing for safer and more effective treatment options. The acquisition was made possible through a licensing agreement with Harvard University and includes related assets from Vesigen Therapeutics based in Cambridge, Massachusetts.

The Synergy of Technologies

The integration of ARMMs technology with Turn's existing eTurna® LNP platform marks a significant development in their therapeutic offerings. By leveraging the complementary capabilities of both systems, Turn Biotechnologies can now deliver a wider range of therapeutic cargoes, including gene editors, proteins, and RNA-based treatments, enhancing their capacity to target diverse cell types safely and effectively. This advancement is pivotal for prospective therapies targeting conditions in ophthalmology, dermatology, and immunology, reflecting the company's commitment to innovative solutions in regenerative medicine.

Anja Krammer, CEO of Turn Biotechnologies, expressed her enthusiasm for the acquisition, stating, "The ARMMs technology is crucial in our mission to unlock the potential of epigenetics in healthcare, especially for age-related conditions. By enabling precise delivery of our therapies, we can significantly improve treatment outcomes."

Enhancing Access to Therapies

One of the most exciting aspects of this acquisition is the technology's ability to accommodate larger and more diverse therapeutic cargoes. This capability is set to redefine the landscape of regenerative medicine by enabling more sophisticated approaches to treatment. Preclinical data already suggest that ARMMs technology can successfully deliver therapeutics to a variety of tissues, including critical areas such as the retinal, lung, nervous system, liver, and spleen.

This precision not only enhances the company’s existing pipeline, which includes TRN-001 for skin rejuvenation, but also opens the door to new therapeutic areas. The versatility of the ARMMs technology empowers Turn Biotechnologies to push the boundaries of what is achievable in treating age-related diseases and conditions.

The Future of Regenerative Medicine

As Turn Biotechnologies continues to innovate in the epigenetic space, the acquisition of ARMMs technology has attracted the interest of significant investors, including Bayer Healthcare LLC, Morningside Group Ltd., and Alexandria Ventures. These investments reflect a growing confidence in the future of epigenetic therapies and the transformative potential they hold for addressing a variety of diseases.

Turn Bio’s focus remains on restoring the epigenome to a more youthful state, allowing for the modulation of gene expression to correct or restore normal cellular function in diseases where epigenetics plays a crucial role. This includes conditions such as skin aging, muscle degeneration, and joint degeneration, which are increasingly prevalent in aging populations.

Conclusion

The acquisition of ARMMs technology signifies a major advancement for Turn Biotechnologies in its quest to harness epigenetic science for therapeutic benefit. By utilizing innovative delivery methods that ensure targeted and efficient treatment, Turn Bio is well-positioned to lead the future of regenerative medicine. For more information on their breakthrough technologies and ongoing research, visit Turn Bio’s website.